Clinical status of induction therapy incorporating a hypomethylating agent for newly diagnosed adult acute myeloid leukemia compared to the standard 7+3 regimen
Expert Rev Hematol. 2023 Jul-Dec;16(10):761-771. doi: 10.1080/17474086.2023.2256472. Epub 2023 Sep 8.ABSTRACTINTRODUCTION: Cytarabine and anthracycline combination therapy (7 + 3 regimen) is the standard care for induction chemotherapy in adult patients with acute myeloid leukemia (AML). Although this intensive regimen achieves a high response rate, it is highly toxic, especially in elderly or frail patients. Hypomethylating agents approved initially for high-risk myelodysplastic syndrome had longer survival times than conventional care in elderly patients with newly diagnosed AML.AREAS COVERED: We summarize the latest inf...
Source: Expert Review of Hematology - September 6, 2023 Category: Hematology Authors: Akihiro Ohmoto Shigeo Fuji Source Type: research
Clinical status of induction therapy incorporating a hypomethylating agent for newly diagnosed adult acute myeloid leukemia compared to the standard 7+3 regimen
Expert Rev Hematol. 2023 Sep 8:1-11. doi: 10.1080/17474086.2023.2256472. Online ahead of print.ABSTRACTINTRODUCTION: Cytarabine and anthracycline combination therapy (7 + 3 regimen) is the standard care for induction chemotherapy in adult patients with acute myeloid leukemia (AML). Although this intensive regimen achieves a high response rate, it is highly toxic, especially in elderly or frail patients. Hypomethylating agents approved initially for high-risk myelodysplastic syndrome had longer survival times than conventional care in elderly patients with newly diagnosed AML.AREAS COVERED: We summarize the latest informati...
Source: Expert Review of Hematology - September 6, 2023 Category: Hematology Authors: Akihiro Ohmoto Shigeo Fuji Source Type: research
